TD Private Client Wealth
GILD icon

TD Private Client Wealth’s Gilead Sciences GILD Stock Holding History

TD Private Client Wealth’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$10.6M Buy
71,056
+5,060
+8% +$710K 0.19% 77
2026
Q2 		$8.34M Sell
65,996
-3,925
-6% -$517K 0.15% 91
2026
Q1 		$9.7M Sell
69,921
-13,279
-16% -$1.86M 0.2% 71
2025
Q4 		$10.2M Buy
83,200
+17,944
+27% +$2.18M 0.22% 72
2025
Q3 		$7.24M Buy
65,256
+20,600
+46% +$2.34M 0.16% 89
2025
Q2 		$4.95M Sell
44,656
-569
-1% -$60.6K 0.12% 125
2025
Q1 		$5.07M Sell
45,225
-8,280
-15% -$854K 0.14% 109
2024
Q4 		$4.94M Sell
53,505
-4,004
-7% -$361K 0.14% 112
2024
Q3 		$4.82M Buy
57,509
+5,497
+11% +$419K 0.14% 114
2024
Q2 		$3.57M Sell
52,012
-909
-2% -$60.7K 0.11% 138
2024
Q1 		$3.88M Buy
52,921
+13,515
+34% +$1.04M 0.13% 130
2023
Q4 		$3.19M Sell
39,406
-3,445
-8% -$268K 0.12% 147
2023
Q3 		$3.21M Buy
42,851
+836
+2% +$64.3K 0.14% 146
2023
Q2 		$3.24M Sell
42,015
-21,401
-34% -$1.71M 0.14% 150
2023
Q1 		$5.26M Sell
63,416
-48,704
-43% -$4.03M 0.24% 98
2022
Q4 		$9.6M Sell
112,120
-20,795
-16% -$1.65M 0.45% 41
2022
Q3 		$8.2M Buy
132,915
+11,754
+10% +$741K 0.42% 44
2022
Q2 		$7.49M Buy
121,161
+14,658
+14% +$908K 0.37% 52
2022
Q1 		$6.33M Buy
106,503
+15,578
+17% +$996K 0.27% 80
2021
Q4 		$6.6M Sell
90,925
-17,491
-16% -$1.2M 0.27% 75
2021
Q3 		$7.57M Buy
108,416
+1,116
+1% +$78.4K 0.32% 68
2021
Q2 		$7.39M Buy
107,300
+28,610
+36% +$1.91M 0.32% 71
2021
Q1 		$5.09M Sell
78,690
-2,712
-3% -$175K 0.24% 100
2020
Q4 		$4.74M Buy
81,402
+15,499
+24% +$935K 0.24% 96
2020
Q3 		$4.16M Buy
65,903
+34,388
+109% +$2.38M 0.23% 96
2020
Q2 		$2.42M Sell
31,515
-47,202
-60% -$3.62M 0.14% 159
2020
Q1 		$5.88M Buy
78,717
+5,590
+8% +$386K 0.42% 55
2019
Q4 		$4.75M Buy
+73,127
New +$4.76M 0.28% 79

Other funds holding GILD

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

TD Private Client Wealth's GILD Position: Q3 2026 in Review

TD Private Client Wealth increased its Gilead Sciences (GILD) stake by 7.7% in Q3 2026, buying an estimated $710K and bringing the position to 71,056 shares worth $10.6M. The position accounts for 0.19% of the portfolio, ranked #77.

TD Private Client Wealth first reported a position in GILD in Q4 2019 and has held it in 28 quarters since. 2,060 funds tracked by Wall St. Rank hold GILD as of Q3 2026.

  • TD Private Client Wealth held 71,056 shares of Gilead Sciences worth $10.6M as of Q3 2026.
  • TD Private Client Wealth bought 5,060 Gilead Sciences shares in Q3 2026, an estimated $710K.
  • Gilead Sciences made up 0.19% of TD Private Client Wealth's portfolio in Q3 2026, its #77 holding.
  • TD Private Client Wealth first reported a position in Gilead Sciences in Q4 2019 and has held it in 28 quarters since.
  • 2,060 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2026.

Based on TD Private Client Wealth's 13F filing for Q3 2026, filed 28 Oct 2026.